Lupin Ltd stock (INE326A01037): shares ease in Mumbai ahead of fresh derivatives levels

Lupin Ltd shares in India closed modestly lower on 06/02/2026, with the Mumbai-listed pharma stock edging down around 0.3 percent as traders look to key futures and options levels for 06/03/2026.

Lupin Ltd shares on the National Stock Exchange of India traded around INR 2,250 on 06/02/2026 after closing at INR 2,252.90 on the BSE, a decline of about 0.3 percent from the prior close of INR 2,259.90, according to Business Standard as of 06/02/2026.Business Standard as of 06/02/2026 The Mumbai-based pharmaceutical group, which trades under the ticker LUPIN on NSE and 500257 on BSE in India, therefore slightly underperformed the broader Indian market on the day.

In derivatives trading, Lupin futures settled at INR 2,249.80 on 06/02/2026, down 0.58 percent, with a support level indicated near INR 2,220 and resistance around INR 2,265 for 06/03/2026, according to a Univest options overview dated 06/02/2026.Univest as of 06/02/2026 The put-call ratio for the stock’s derivatives was cited at 1.03 in that report, suggesting balanced positioning among traders ahead of Wednesday’s session.

The stock traded at INR 2,252.90 on 06/02/2026 on the BSE in Mumbai, per the same Business Standard price snapshot, implying a market capitalization of roughly INR 1.03 trillion for the Indian drugmaker.Business Standard as of 06/02/2026 In Germany, Lupin is also available for retail investors via platforms such as Tradegate, typically quoted in euros, though liquidity and pricing there generally follow the Indian primary listing.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Lupin
• Sector/industry: Pharmaceuticals and generics
• Headquarters/country: Mumbai, India
• Core markets: India, United States, select markets in Europe and emerging regions
• Key revenue drivers: Generic formulations, branded generics, specialty and complex generics, and active pharmaceutical ingredients
• Home exchange/listing venue: NSE India (LUPIN), BSE India (500257)
• Trading currency: INR

Lupin Ltd: core business model

Lupin focuses on developing and supplying generic and specialty pharmaceutical products, with earnings largely generated from oral solid generics, branded formulations and an expanding US portfolio in complex and respiratory therapies.

Lupin Ltd in peer comparison

Compared with domestic peer Cipla, Lupin shows a similar equity valuation scale in India, with Cipla’s stock at INR 1,312.65 and a market capitalization near INR 106,033 crore and Lupin at INR 2,304.45 with a market value of about INR 105,323 crore as of 03/05/2026, according to a BlinkX comparison as of 03/05/2026.BlinkX as of 03/05/2026 That comparison underscores how investors currently price both Indian pharma names in a similar range despite differing product mixes and geographic exposures.

Sector-wide, an Indian pharma overview on 06/02/2026 highlighted that Lupin has been among the stronger performers in the United States market, with its US business rising nearly 40 percent year-on-year to about USD 1.3 billion, as Indian companies push deeper into specialty drugs, respiratory therapies and complex generics.Rediff as of 06/02/2026 In that context, Lupin sits in a competitive peer set that includes Sun Pharma, Cipla and Zydus Lifesciences, all of which are stepping up US investments and selective local manufacturing for higher-value products.

Conclusion

Lupin Ltd’s modest share price decline around INR 2,250 on the Indian exchanges on 06/02/2026 comes as derivatives traders watch closely defined support and resistance levels for 06/03/2026. In a peer framework, the group’s valuation and scale are comparable with other major Indian pharmacy players such as Cipla, while its strong US revenue growth and shift into specialty and complex products keep the company positioned in a key strategic segment of the global generics industry.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.